Oxidized low density lipoprotein and total antioxidant capacity in type-2 diabetic and impaired glucose tolerance Saudi men

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Nour Eldin, Essam Eldin Mohamed ^a   Almarzouki, Abdullah ^a   Assiri, Adel Mohamed ^a   Elsheikh, Osman Mohammed ^b   Mohamed, Badreldin Elsonni Abdalla ^c   Babakr, Abdullatif Taha ^a  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Malondialdehyde (MDA); Oxidized LDL (Ox LDL); Prediabetics; Total antioxidant capacity

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL STATE; SAUDI; STRUCTURED QUESTIONNAIRE; TOTAL ANTIOXIDANT CAPACITY;

EID: 84907999343     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-94     Document Type: Article

References (43)

1. Zuliani G, Morieri ML, Volpato S, Vigna GB, Tch CB, Maggio M, Cherubini A, Bandinelli S, Guralnik JM, Ferrucci L: Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study. Atherosclerosis 2013, 226:201-207.
2. Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G, the DCCT/EDIC Research Group: Sunday, 26 August 2012. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Eur Heart J 2012, 33:19-338.
3. Perrin-Cocon L, Diaz O, Andre P, Lotteau V: Modified lipoproteins provide lipids that modulate dendritic cell immune function. Biochimie 2013, 95:103-108.
4. Kaplan M, Aviram M, Hayek T: Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacol Ther 2012, 136:175-185.
5. El-Bassiouni EA, Helmy MH, El-Zoghby SM, El-Nabi Kamel MA, Hosny RM: Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients. Br J Biomed Sci 2007, 64:109-116.
6. Yang H, Mohamed AS, Zhou SH: Oxidized low density lipoprotein, stem cells, and atherosclerosis. Lipids Health Dis 2012, 11:85.
7. Ishigaki Y, Oka Y, Katagiri H: Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol 2009, 20:363-369.
8. Tsimikas S, Miller YI: Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 2011, 17:27-37.
9. Wang Y, Chun OK, Song WO: Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. Nutrients 2013, 5:2969-3004.
10. Rajkovic N, Zamaklar M, Lalic K, Lalic NM, Popovic L, Draskovic-Radojkovic D, Singh S, Stosic L, Jotic A, Lukic L, Milicic T: OP3: Oxidized LDL as residual lipid risk marker in type 2 diabetes. Diabetes Metab 2012, 38 (Supplement 5):S98-S99.
11. Kosola J, Vaara JP, Ahotupa M, Kyrolainen H, Santtila M, Oksala N, Atalay M, Vasankari T: Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men. Metabolism 2013, 62:992-999.
12. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
13. Holvoet P, Macy E, Landeloos M, Jones D, Jenny NS, Van de Werf F, Tracy RP: Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006, 52:760-764.
14. Miller NJ, Rice-Evans CA: Factors influencing the antioxidant activity determined by the ABTS. + radical cation assay. Free Radic Res 1997, 26:195-199.
15. Dawn-Linsley M, Ekinci FJ, Ortiz D, Rogers E, Shea TB: Monitoring thiobarbituric acid-reactive substances (TBARs) as an assay for oxidative damage in neuronal cultures and central nervous system. J Neurosci Methods 2005, 141:219-222.
16. Matsumoto H, Uchino M, Kato M: Evaluation of haemoglobin A1c measurement by an enzymaticmethod using an automated analyser that has an on-board haemolysis system. Ann Clin Biochem 2013, 50:443-449.
17. Matsuda M, Tamura R, Kanno K, Segawa T, Kinoshita H, Nishimoto O, Nishiyama H, Kawamoto T: Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statintreated diabetes patients with coronary artery disease. Diabetology Metab Syndrome 2013, 5:77.
18. Gomez M, Molina L, Bruguera J, Sala J, Masia R, Munoz-Aguayo D, Tomas M, Heredia S, Blanchart G, Gaixas S, Vila J, Fito M: Oxidized low-density lipoprotein antibodies in myocardial infarction patients without classical risk factors. J Cardiovasc Med (Hagerstown) 2014, 15:417-422.
19. Li S, Kievit P, Robertson AK, Kolumam G, Li X, von Wachenfeldt K, Valfridsson C, Bullens S, Messaoudi I, Bader L, Cowan KJ, Kamath A, van Bruggen N, Bunting S, Frendeus B, Grove KL: Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab 2013, 2:256-269.
20. Rahman K: Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging 2007, 2:219-236.
21. Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M, Kuhne H, Julius U, Graessler J: In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 2002, 51:3102-3106.
22. Di Renzo L, Carraro A, Valente R, Iacopino L, Colica C, De Lorenzo A: Intake of red wine in different meals modulates oxidized LDL level, oxidative and inflammatory gene expression in healthy people: a randomized crossover trial. Oxid Med Cell Longev 2014, 2014:681318.
23. Castilla P, Echarri R, Davalos A, Cerrato F, Ortega H, Teruel JL, Lucas MF, Gomez-Coronado D, Ortuno J, Lasuncion MA: Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr 2006, 84:252-262.
24. Hirano-Ohmori R, Takahashi R, Momiyama Y, Taniguchi H, Yonemura A, Tamai S, Umegaki K, Nakamura H, Kondo K, Ohsuzu F: Green tea consumption and serum malondialdehyde-modified LDL concentrations in healthy subjects. J Am Coll Nutr 2005, 24:342-346.
25. Baba S, Natsume M, Yasuda A, Nakamura Y, Tamura T, Osakabe N, Kanegae M, Kondo K: Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo- and hypercholesterolemic humans after intake of different levels of cocoa powder. J Nutr 2007, 137:1436-1441.
26. Basu A, Betts NM, Ortiz J, Simmons B, Wu M, Lyons TJ: Low-energy cranberry juice decreases lipid oxidation and increases plasma antioxidant capacity in women with metabolic syndrome. Nutr Res 2011, 31:190-196.
27. Winklhofer-Roob BM, Rock E, Ribalta J, Shmerling DH, Roob JM: Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies. Mol Aspects Med 2003, 24:391-402.
28. Folchetti LD, Monfort-Pires M, de Barros CR, Martini LA, Ferreira SR: Association of fruits and vegetables consumption and related-vitamins with inflammatory and oxidative stress markers in prediabetic individuals. Diabetology Metab Syndrome 2014, 6:22.
29. American Diabetes A: Diagnosis and classification of diabetes mellitus. Diabetes Care 2014, 37(Suppl 1):S81-S90.
30. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A: Diabetes mellitus in Saudi Arabia. Saudi Med J 2004, 25:1603-1610.
31. Whiting DR, Guariguata L, Weil C, Shaw J: IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
32. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Yousef M, Sabico SL, Chrousos GP: Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic. BMC Med 2011, 9:76.
33. Schwenke DC, D'Agostino RB Jr, Goff DC Jr, Karter AJ, Rewers MJ, Wagenknecht LE: Differences in LDL oxidizability by glycemic status: the insulin resistance atherosclerosis study. Diabetes Care 2003, 26:1449-1455.
34. Salmon AB: Oxidative stress in the etiology of age-associated decline in glucose metabolism. Longevity Healthspan 2012, 1:7.
35. Caparevic Z, Kostic N: [The influence of age and the beginning of menopause on the lipid status, LDL oxidation, and CRP in healthy women]. Srp Arh Celok Lek 2007, 135:280-285.
36. Li Y, Saito M, Tobimatsu S, Oshida H, Hori Y, Fuchigami H, Munakata H, Nakajima K: Prediabetes and impaired lung function in asymptomatic adults. Diabetes Res Clin Pract 2013, 100:e51-e54.
37. Luca AC, Iordache C: Obesity-a risk factor for cardiovascular diseases. Rev Med Chir Soc Med Nat Iasi 2013, 117:65-71.
38. Ma RC, Lee HM, Lam VK, Tam CH, Ho JS, Zhao HL, Guan J, Kong AP, Lau E, Zhang G, Luk A, Wang Y, Tsui SK, Chan TF, Hu C, Jia WP, Park KS, Lee HK, Furuta H, Nanjo K, Tai ES, Ng DP, Tang NL, Woo J, Leung PC, Xue H, Wong J, Leung PS, Lau TC, Tong PC, et al: Familial young-onset diabetes, pre-diabetes and cardiovascular disease are associated with genetic variants of DACH1 in Chinese. PLoS One 2014, 9:e84770.
39. Ng DS: Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Can J Diabetes 2013, 37:319-326.
40. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR: Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 1999, 222:178-184.
41. Magge SN, Prasad D, Koren D, Gallagher PR, Mohler ER 3rd, Stettler N, Levitt Katz LE, Rader DJ: Prediabetic obese adolescents have a more atherogenic lipoprotein profile compared with normoglycemic obese peers. J Pediatr 2012, 161:881-886.
42. Khan HA, Sobki SH, Khan SA: Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 2007, 7:24-29.
43. Habib SS: Body mass index and body fat percentage in assessment of obesity prevalence in saudi adults. Biomed Environ Sci 2013, 26:94-99.